Price range: $125.00 through $225.00
Contents: Retatrutide
Form: Lyophilized Powder
Purity: ≥ 99% pure
Emerging Research Evidence:
This “triple – agonist” peptide provides significant weight loss, reduces hunger and cravings, lowers blood pressure and lipids, provides blood sugar regulation and reduces liver fat.
Keep product in cool, dark place.
Sold for Research Use Only / Not FDA Regulated
GLP-1 / GIP / Glucagon Agonist (Retatrutide) Overview
Retatrutide is a groundbreaking next-generation triple agonist targeting glucagon receptors, gastric inhibitory polypeptide, and glucagon-like peptide-1, synergistically enhancing insulin secretion, improving glucose homeostasis, and refining appetite modulation. The glucagon receptors are even more comprehensive than Tirzepatide. It’s being studied for obesity/overweight and related metabolic conditions. Research is showing substantial weight reduction over 24–48 weeks in adults with obesity. Research is ongoing and the claimed benefits are still emerging.
Retatrutide Structure:
CAS Number: 2381089-83-2
Molecular Formula: C₂₂₁H₃₄₂N₄₆O₆₈
Molecular Weight (average): 4731.34 g/mol
Monoisotopic (Exact) Mass: 4728.4718 Da
Parent Compound: N/A – engineered chimeric incretin/glucagon peptide; not derived from a single parent molecule.
Synonyms:
Research Areas:
Research-only note: GLP-1 / GIP / Glucagon Agonist – R is not FDA-approved for therapeutic use; published effects are primarily preclinical and exploratory.
| Size | 5mg, 10mg, 20mg, 30mg, 50mg |
|---|
For Research Use Only — Not for Human or Veterinary Use. Not evaluated or approved by the FDA. Not intended to diagnose, treat, cure, or prevent any disease. All information on this website is provided strictly for laboratory research and educational purposes. Nothing herein constitutes medical, clinical, or legal advice, nor an endorsement of non-laboratory use. Any discussion of specific peptides or potential research findings is informational only and must not be interpreted as guidance for use in or on humans or animals.
